Time of administration important? Morning versus evening dosing of valsartan. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Zappe, Dion H.; Crikelair, Nora; Kandra, Albert; Palatini, Paolo
• Is Part Of: Journal of hypertension. Volume 33:Issue 2(2015:Feb.)
• Publication Date: 2015-02
• Subjects: Hypertension -- Periodicals; Hypertension -- Periodicals; 616.132005
• DOI: 10.1097/HJH.0000000000000397
• Languages: English
• ISSNs: 1473-5598

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Objective:</title> <p>Studies suggest that bedtime dosing of an angiotensin-converting enzyme (ACE)-inhibitor or angiotensin receptor blocker shows a more sustained and consistent 24-h antihypertensive profile, including greater night-time blood pressure (BP) reduction. We compared the antihypertensive effects of morning (a.m.) and evening (p.m.) dosing of valsartan on 24-h BP.</p> </sec> <sec> <title>Methods:</title> <p>This 26-week, multicentre, randomized, double-blind study evaluated the efficacy and safety of valsartan 320 mg, dosed a.m. or p.m., versus lisinopril 40 mg (a.m.), a long-acting ACE-inhibitor, in patients with grade 1–2 hypertension and at least one additional cardiovascular risk factor. Patients (<italic>n</italic> = 1093; BP = 156 ± 11/91 ± 8 mmHg; 62 years, 56% male, 99% white) received (1 : 1 : 1) valsartan 160 mg a.m. or p.m. or lisinopril 20 mg a.m. for 4 weeks, then force-titrated to double the initial dose for 8 weeks. At Week 12, hydrochlorothiazide (HCTZ) 12.5 mg was added for 14 weeks if office BP was more than 140/90 mmHg and/or ambulatory BP more than 130/80 mmHg.</p> </sec> <sec> <title>Results:</title> <p>Mean 24-h ambulatory SBP change from baseline to Weeks 12 and 26 was comparable between valsartan a.m. (–10.6 and –13.3 mmHg) and p.m. (–9.8 and –12.3 mmHg) and lisinopril (–10.7 and –13.7 mmHg). There was no benefit of valsartan p.m. versus a.m. on night-time BP, early morning BP and morning BP surge. Evening dosing also did not improve BP lowering in patients requiring add-on HCTZ or in nondippers at baseline. All treatments were well tolerated.</p> </sec> <sec> <title>Conclusion:</title> <p>Once-daily dosing of valsartan 320 mg results in equally effective 24-h BP efficacy, regardless of dosing time.</p> </sec> <sec> <title>Trial Registration:</title> <p>ClinicalTrials.gov Identifier: NCT00241124.</p> </sec> </abstract>